Freenome, Inc. (FRNM) vs Korsana Biosciences, Inc. (KRSA)

A side-by-side comparison of Freenome, Inc. and Korsana Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

FRNM

Freenome, Inc.

$138M

$16.98HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

KRSA

Korsana Biosciences, Inc.

$147M

$31.34HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT

Total return — FRNM vs KRSA

growth of $100 · dividends reinvested · last 1y

FRNM +52.9% (+52.9%/yr)KRSA +37.1% (+37.1%/yr)FRNM compounded faster over this window

FRNM KRSA

Metrics side by side

Total return (annualized)

Metric	FRNM	KRSA
Total return (1Y)	N/A	75.07%
Total return CAGR (3Y)	N/A	11.57%
Total return CAGR (5Y)	N/A	-40.41%

FRNM is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full FRNM analysis Full KRSA analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.